Zai Lab Ltd.
http://www.zailaboratory.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zai Lab Ltd.
Argenx Advances Efgartigimod Into China With Zai Lab Pact
Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.
Finance Watch: Inhibikase IPO Brought 2020 US Total To 86
Public Company Edition: The new year started with two companies signaling plans for significant near-term initial public offerings, following Inhibikase’s launch as the last IPO of 2020. Other recent financial highlights include layoffs at Calithera and Regenxbio’s $200m Zolgensma royalty sale.
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Five Prime Lands Blow On Gastric Cancers With FGFR2b Antibody
A potential first-in-class FGFR2b-targeted monoclonal antibody, bemarituzumab, has shown top-line benefits in the Phase II FIGHT study in advanced gastric or gastroesophageal junction cancers.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Zai Lab Limited
- Zai Lab (Shanghai) Co., Ltd.